TDI01

Phase 3Small molecule

BBeijing Tide Pharmaceutical Co., Ltd

TDI01 is one of 45 small molecule programs targeting Idiopathic Pulmonary Fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary FibrosisActive, not recruiting

Idiopathic Pulmonary FibrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Phase 3

2 2

Tracleer

Johnson & Johnson

Phase 3

2 3

Prevacid

Takeda

Phase 3

1 4

Letairis

Gilead

Phase 3

1 5

Gleevec

Novartis

Phase 3

1 6

MS Contin

Coumadin

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 9

Jascayd

Boehringer Ingelheim

Phase 3

1 10

Bactrim

UUniversity of California, San Francisco

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Active, not recruiting

Chronic Graft-Versus-Host Disease (cgvhd)

NCT06169722

Q4 2029

Phase 3Recruiting

Idiopathic Pulmonary Fibrosis

NCT07464912

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis2 trials

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Unknown status·BBeijing Tide Pharmaceutical Co., Ltd·Phase 2·NCT06102083·120 enrolled

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 3·NCT07464912·508 enrolled

Chronic Graft-Versus-Host Disease (cGVHD)1 trial

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

Active, not recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 1/2·NCT06169722·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TDI01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TDI01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TDI01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tide Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Tide Pharmaceutical Co., Ltd

TDI01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis2 trials

Chronic Graft-Versus-Host Disease (cGVHD)1 trial

References

Drug Info

Quick Facts

Related News